Complete Set of Claims Pursuant to 37 C.F.R. § 1.121(c)(3)

28.   A method for therapeutically or prophylactically treating atherosclerosis in a human or other animal in need of treatment thereof comprising administering to said human or other animal a vaccine peptide in a pharmaceutically acceptable buffer, said vaccine peptide comprising a helper T cell epitope portion comprising a helper T cell epitope and B cell epitope portion comprising a B cell epitope of CETP.

29.   The method for treating atherosclerosis according to claim 28 wherein said helper T cell epitope portion comprises a helper T cell epitope derived from an antigenic peptide selected from the group consisting of tetanus toxoid, diphtheria toxoid, pertussis vaccine, Bacile Calmette Guerin (BCG), polio vaccine, measles vaccine, mumps vaccine, rubella vaccine, purified protein derivative of tuberculin, keyhole limpet hemocyanin, hsp70, and combinations thereof.

37.   The method according to claim 28, wherein the B cell epitope portion of the vaccine peptide comprises a carboxyl terminal region of human CETP consisting of between 6 and 26 consecutive amino acids of SEQ ID NO:1.

38.   The method according to claim 37, wherein the vaccine peptide comprises the amino acid sequence of SEQ ID NO:2.

39.   The method according to claim 37, wherein the vaccine peptide comprises a dimer of the amino acid sequence of SEQ ID NO:2.